Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection
Abstract Background Dalbavancin is a lipoglycopeptide antibiotic approved for treatment of skin and soft tissue infections, administered as a single or two-dose treatment. The extended half-life, good penetration into bone and synovial fluid, and bactericidal activity against gram-positive bacteria,...
Main Authors: | Anna Lange, Ulrica Thunberg, Bo Söderquist |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-10-01
|
Series: | BMC Infectious Diseases |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12879-023-08709-8 |
Similar Items
-
Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review
by: Luis Buzón-Martín, et al.
Published: (2021-05-01) -
Dalbavancin Use in Bone and Joint Infections
by: Liam P. Alderson, BS, et al.
Published: (2024-12-01) -
Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety
by: Andrés Ruiz-Sancho, et al.
Published: (2023-06-01) -
<i>Corynebacterium striatum</i> Prosthetic Joint Infection Successfully Treated with Long-Term Dalbavancin
by: Bo Söderquist, et al.
Published: (2023-02-01) -
Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections
by: Altea Gallerani, et al.
Published: (2023-11-01)